- Home
- UFPI vs SYRE Comparison
UFPI vs SYRE Comparison
Compare UFPI & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UFPI | SYRE |
|---|---|---|
| Founded | 1955 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.5B |
| IPO Year | 2011 | 2015 |
Fundamental Metrics
Financial Performance| Metric | UFPI | SYRE |
|---|---|---|
| Price | $89.19 | $84.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $104.33 | $85.08 |
| AVG Volume (30 Days) | 466.0K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $3,941,182,000.00 | N/A |
| Revenue This Year | $2.04 | N/A |
| Revenue Next Year | $5.61 | N/A |
| P/E Ratio | $100.21 | ★ N/A |
| Revenue Growth | ★ 21.62 | N/A |
| 52 Week Low | $77.89 | $14.51 |
| 52 Week High | $118.00 | $102.06 |
Technical Indicators
Market Signals| Indicator | UFPI | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 52.59 |
| Support Level | $88.09 | $81.65 |
| Resistance Level | $94.09 | $102.06 |
| Average True Range (ATR) | 2.59 | 4.79 |
| MACD | 0.55 | -0.55 |
| Stochastic Oscillator | 58.15 | 19.59 |
Price Performance
Historical ComparisonAbout UFPI UFP Industries Inc.
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate. It describes itself as an innovation company, a logistics company, a design company, an engineering and value-added product and solutions company.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.